Espen Rusten1, Bernt Louni Rekstad1, Christine Undseth2, Dagmar Klotz3, Eivor Hernes4, Marianne Grønlie Guren2,5, Eirik Malinen1,6. 1. 1 Department of Medical Physics, University of Oslo , Oslo , Norway. 2. 2 Department of Oncology, University of Oslo , Oslo , Norway. 3. 3 Department of Pathology, University of Oslo , Oslo , Norway. 4. 4 Department of Nuclear Medicine, University of Oslo , Oslo , Norway. 5. 5 K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital , Oslo , Norway. 6. 6 Department of Physics, University of Oslo , Oslo , Norway.
Abstract
OBJECTIVE: To assess the role of [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET), obtained before and during chemoradiotherapy, in predicting locoregional failure relative to clinicopathological factors for patients with anal cancer. METHODS: 93 patients with anal squamous cell carcinoma treated with chemoradiotherapy were included in a prospective observational study (NCT01937780). FDG-PET/CT was performed for all patients before treatment, and for a subgroup (n = 39) also 2 weeks into treatment. FDG-PET was evaluated with standardized uptake values (SUVmax/peak/mean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and a proposed Z-normalized combination of MTV and SUVpeak (ZMP). The objective was to predict locoregional failure using FDG-PET, tumor and lymph node stage, gross tumor volume (GTV) and human papilloma virus (HPV) status in univariate and bivariate Cox regression analysis. RESULTS: N3 lymph node stage, HPV negative tumor, GTV, MTV, TLG and ZMP were in univariate analysis significant predictors of locoregional failure (p < 0.01), while SUVmax/peak/mean were not (p > 0.2). In bivariate analysis HPV status was the most independent predictor in combinations with N3 stage, ZMP, TLG, and MTV (p < 0.02). The FDG-PET parameters at 2 weeks into radiotherapy decreased by 30-40 % of the initial values, but neither absolute nor relative decrease improved the prediction models. CONCLUSION: Pre-treatment PET parameters are predictive of chemoradiotherapy outcome in anal cancer, although HPV negativity and N3 stage are the strongest single predictors. Predictions can be improved by combining HPV with PET parameters such as MTV, TLG or ZMP. PET 2 weeks into treatment does not provide added predictive value. ADVANCES IN KNOWLEDGE: Pre-treatment PET parameters of anal cancer showed a predictive role independent of clinicopathological factors. Although the PET parameters show substantial reduction from pre- to mid-treatment, the changes were not predictive of chemoradiotherapy outcome.
OBJECTIVE: To assess the role of [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET), obtained before and during chemoradiotherapy, in predicting locoregional failure relative to clinicopathological factors for patients with anal cancer. METHODS: 93 patients with anal squamous cell carcinoma treated with chemoradiotherapy were included in a prospective observational study (NCT01937780). FDG-PET/CT was performed for all patients before treatment, and for a subgroup (n = 39) also 2 weeks into treatment. FDG-PET was evaluated with standardized uptake values (SUVmax/peak/mean), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and a proposed Z-normalized combination of MTV and SUVpeak (ZMP). The objective was to predict locoregional failure using FDG-PET, tumor and lymph node stage, gross tumor volume (GTV) and human papilloma virus (HPV) status in univariate and bivariate Cox regression analysis. RESULTS: N3 lymph node stage, HPV negative tumor, GTV, MTV, TLG and ZMP were in univariate analysis significant predictors of locoregional failure (p < 0.01), while SUVmax/peak/mean were not (p > 0.2). In bivariate analysis HPV status was the most independent predictor in combinations with N3 stage, ZMP, TLG, and MTV (p < 0.02). The FDG-PET parameters at 2 weeks into radiotherapy decreased by 30-40 % of the initial values, but neither absolute nor relative decrease improved the prediction models. CONCLUSION: Pre-treatment PET parameters are predictive of chemoradiotherapy outcome in anal cancer, although HPV negativity and N3 stage are the strongest single predictors. Predictions can be improved by combining HPV with PET parameters such as MTV, TLG or ZMP. PET 2 weeks into treatment does not provide added predictive value. ADVANCES IN KNOWLEDGE: Pre-treatment PET parameters of anal cancer showed a predictive role independent of clinicopathological factors. Although the PET parameters show substantial reduction from pre- to mid-treatment, the changes were not predictive of chemoradiotherapy outcome.
Authors: Marco H M Janssen; Michel C Ollers; Robert G Riedl; Jørgen van den Bogaard; Jeroen Buijsen; Ruud G P M van Stiphout; Hugo J W L Aerts; Philippe Lambin; Guido Lammering Journal: Int J Radiat Oncol Biol Phys Date: 2009-07-29 Impact factor: 7.038
Authors: Laia Alemany; Maëlle Saunier; Isabel Alvarado-Cabrero; Beatriz Quirós; Jorge Salmeron; Hai-Rim Shin; Edyta C Pirog; Núria Guimerà; Gustavo Hernandez-Suarez; Ana Felix; Omar Clavero; Belen Lloveras; Elena Kasamatsu; Marc T Goodman; Brenda Y Hernandez; Jan Laco; Leopoldo Tinoco; Daan T Geraets; Charles F Lynch; Vaclav Mandys; Mario Poljak; Robert Jach; Josep Verge; Christine Clavel; Cathy Ndiaye; JoEllen Klaustermeier; Antonio Cubilla; Xavier Castellsagué; Ignacio G Bravo; Michael Pawlita; William G Quint; Nubia Muñoz; Francesc X Bosch; Silvia de Sanjosé Journal: Int J Cancer Date: 2014-05-30 Impact factor: 7.396
Authors: Siamak Mohammadkhani Shali; Vanessa Schmitt; Florian F Behrendt; Oliver H Winz; Alexander Heinzel; Felix M Mottaghy; Michael J Eble; Frederik A Verburg Journal: Eur J Radiol Date: 2016-05-20 Impact factor: 3.528
Authors: Leonard L Gunderson; Jennifer Moughan; Jaffer A Ajani; John E Pedersen; Kathryn A Winter; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher G Willett Journal: Int J Radiat Oncol Biol Phys Date: 2013-09-10 Impact factor: 7.038
Authors: Roger D James; Robert Glynne-Jones; Helen M Meadows; David Cunningham; Arthur Sun Myint; Mark P Saunders; Timothy Maughan; Alec McDonald; Sharadah Essapen; Martin Leslie; Stephen Falk; Charles Wilson; Simon Gollins; Rubina Begum; Jonathan Ledermann; Latha Kadalayil; David Sebag-Montefiore Journal: Lancet Oncol Date: 2013-04-09 Impact factor: 41.316